1227853-05-5

Basic information

• Product Name: N⁽¹⁾-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N,N-dimethylformamidine
• Synonyms: N⁽¹⁾-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N,N-dimethylformamidine
• CAS NO: 1227853-05-5
• Molecular Weight: 306.767
• Mol File: 1227853-05-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N⁽¹⁾-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N,N-dimethylformamidine(CAS DataBase Reference)
• NIST Chemistry Reference: N⁽¹⁾-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N,N-dimethylformamidine(1227853-05-5)
• EPA Substance Registry System: N⁽¹⁾-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N,N-dimethylformamidine(1227853-05-5)

Safety Data

• Hazardous Substances Data: 1227853-05-5(Hazardous Substances Data)

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 

Downstream Products

• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 1227853-09-9 N⁽¹⁾-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N,N-dimethylformamidine hydrochloride 
• 231277-92-2 lapatanib 
• 1227853-06-6 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylimino)methyl)furan-2-yl)quinazolin-4-amine 
• 388082-78-8 lapatinib ditosylate 
• 231278-84-5 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde 

Relevant articles and documents

Lapatinib intermediate and its preparation method and application

The invention discloses a lapatinib intermediate as well as a preparation method and application thereof. The lapatinib intermediate contains chemical structures respectively shown in a formula IV, a formula V and a formula VIII (described in the specification). The lapatinib intermediate provided by the invention has the advantages of simple preparation technology, available raw materials, mild reaction conditions, high yield, easy control on quality and the like; by applying the lapatinib intermediate, a preparation route of lapatinib can be shortened, operation is simple, reaction conditions are mild, especially adoption of poisonous reagents such as sulfoxide chloride and phosphorus oxychloride can be avoided, the lapatinib intermediate can be stable in each step, post treatment is simple, yield is high, the lapatinib intermediate is applicable to mass production and has practical value, and large-scale industrial production demand of lapatinib can be met.

A NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to an improved and novel process for the preparation of high purity crystalline base of Lapatinib of formula-(l) having chemical name N-{3-chloro-4-[(3- fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesuIfonyl) ethyl]amino}methyl]-2-furyl]-4-quin - azolinamine and its pharmaceutically acceptable salts. The present invention further relates to intermediates according to formula (8) and formula (9) used in this process